Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BRISTOL-MYERS WILL CO-DEVELOP COLLAGEN's FIRST DRUG TGFb2, under a joint R&D agreement announced Aug. 31. "Bristol-Myers will supply recombinant transforming growth factor beta, type 2 (TGFb2) and make a major investment in the development of TGFb2-based products for the dermatology market with Collagen over the next five years," Collagen said. "Collagen and Bristol-Myers will co-market these products worldwide." Human clinicals of TGFb2 for treatment of psoriasis are more than a year away (scheduled for the fourth quarter of 1989). The product will also be studied for other immune-based skin diseases including eczema. Collagen estimates that about 4 mil. Americans suffer from eczema and psoriasis. In addition, Bristol has acquired for $ 1 mil. an option for exclusive marketing rights to other applications of TGFb2, such as cancer, organ transplantation, and other immune-related diseases. "In laboratory studies conducted by [Collagen R&D subsidiary] Celtrix, TGFb2 has shown to be over 100,000 times more potent than cyclosporine-A," the release maintains. "Early research also indicates the potential for TGFb2 to differentiate between healthy and abnormal cells, which may lead to novel cancer therapies." In the same release, Collagen announced the granting of TGFb2 patent claims in the U.S. for immune suppression and cancer therapy. The cancer application is owned jointly with Bristol, whose Genetics Systems Division has been collaborating with Collagen. A U.S. patent issued for the TGFb2 protein in March 1988, Collagen said. "Our strong patent position, coupled with our collagen-based matrix technology and Bristol-Myers' expertise in pharmaceuticals, puts us in the dominant position to develop therapeutic products using TGFb2," Celtrix President Bruce Pharriss, PhD, contended. Based in Palo Alto, Collagen's core business has been the development of purified collagen products for tissue augmentation, including bone graft substitutes for orthopedic applications and dermal ulcer repair. Collagen closed fiscal 1988 (June 30) with sales of $ 29.1 mil., up from $ 24.3 mil. in 1987. In 1987, the company created Celtrix to handle R&D activities based on the company's cellular matrix technology.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts